Exicure, Inc.

NasdaqCM XCUR

Exicure, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -6.54

Exicure, Inc. Price to Earnings Ratio (P/E) is -6.54 on January 14, 2025, a -1,182.12% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Exicure, Inc. 52-week high Price to Earnings Ratio (P/E) is -0.30 on June 27, 2024, which is 95.49% above the current Price to Earnings Ratio (P/E).
Exicure, Inc. 52-week low Price to Earnings Ratio (P/E) is -20.80 on November 27, 2024, which is -218.20% below the current Price to Earnings Ratio (P/E).
Exicure, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -2.42.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqCM: XCUR

Exicure, Inc.

CEO	Mr. Paul Kang
IPO Date	May 22, 2018
Location	United States
Headquarters	2430 North Halsted Street
Employees	5
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

Key trends

Past 5 years